


2026

Catalog

promise
ADVANCED PROTEOMICS

SIL-mAbs

FOR TARGETED LC-MS QUANTIFICATION



Improve accuracy across your Mass Spectrometry workflows

www.promise-proteomics.com | contact@promise-proteomics.com

SIL-MONOCLONAL ANTIBODIES

PROMISE Proteomics is a pioneer and an expert in the development of Mass Spectrometry-based quantification methods and in the bioproduction of Stable-Isotope-Labelled (SIL) monoclonal Antibodies (mAbs).

Why use our SIL-mAbs ?

A SIL form of an analyte protein is widely regarded as the optimal internal standard¹ for absolute quantification of proteins using LC-MS.

SIL-mAbs correct bias (due to incomplete digestion, losses, adsorption, proteolysis, etc.) occurring during the preparation and analytical workflow. With SIL-mAbs, the accuracy and reproducibility of your quantification data is improved.


This product is useful for:

- Bioanalysis pharmacokinetics studies (clinical & non-clinical),
- Research & Discovery as well as pre-clinical & clinical Drug Development

Characteristics

- Full length recombinant monoclonal antibodies
- High isotopic incorporation (>98%) and purity (>95%)
- Labelling on Arg, Lys residues, $^{13}\text{C}^{15}\text{N}$ isotope
- Expression systems CHO or HEK

How to use our solutions?



Unlike the use of SIL-peptides, Promise's SIL-mAbs are processed along with the target analytes throughout the pre-analytical and LC-MS workflow thus improving robustness and quality of the quantitative data.

1. Todoroki, K. *et al.* (2020, février). Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates : A review of recent advances and future perspectives. *Journal of Pharmaceutical and Biomedical Analysis*, 179, 112991. <https://doi.org/10.1016/j.jpba.2019.112991>

OFF-THE-SHELF PRODUCTS

SIL-mAbs* are available to support your studies and clinical trials.

Your mAb of interest is not listed? Please contact our experts for custom bioproduction.

SIL-mAbs	REFERENCES	SIL-mAbs	REFERENCES
Abatacept	ORF90261	Golimumab	SIU05281
Adalimumab	HUU05211	Guselkumab	TRU05271
Aflibercept	AFF90271	Infliximab	REX08151
Alemtuzumab	ALZ10131	Inotuzumab	INZ13241
Avelumab	BAU05571	Ipilimumab	YEU05271
Belatacept	<i>upon request</i>	Ixekizumab	TAZ13261
Bevacizumab	AVZ10161	Mirikizumab	OMZ13191
Brentuximab	BRX08181	Natalizumab	TYZ13211
Cetuximab	ERX08221	Nivolumab	OPU08201
Concizumab	COZ13241	Obinutuzumab- <i>Like</i>	GAH92161
Crovalimab	PIZ10191	Ocrelizumab	OCZ10231
Daratumumab	DAU05201	Pembrolizumab	KEZ13331
Datopotamab	DAZ10161	Pertuzumab	PEZ10191
Dinutuximab	DIX08251	Polatuzumab	POZ10211
Dupilumab	DUU08301	Risankizumab	SKZ10121
Durvalumab	IMU05501	Rituximab	RIX08221
Eculizumab	SOZ11141	Sacituzumab	SAZ10141
Emicizumab- <i>Like</i>	HEH95561	Secukinumab	COU05201
Enfortumab	PAZ10201	Siltuximab	SYX08151
Epcoritamab	EPZ10171	Tocilizumab	ACZ10241
Etanercept	ENF90251	Trastuzumab	HEZ10231
Frexalimab	FRZ10201	Ustekinumab	STU05261
		Vedolizumab	ENZ10211

**for Research Use Only*



✉ contact@promise-proteomics.com

REFERENCES

Peer reviewed publications using our SIL-mAbs

- **Mayo Clinic**

Ladwig, P. *et al.* (2024). Infliximab Therapeutic monitoring by tryptic peptide LC-MS/MS method improvements lead to improved accuracy with decreased imprecision and turnaround time. *Journal of Mass Spectrometry and Advances in the Clinical Lab*, 32, 24-30. <https://doi.org/10.1016/j.jmsacl.2024.01.007>

- **Hospices Civils de Lyon**

Millet, A. *et al.* (2021). Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa. *Biomedicines*, 9(6), 621. <https://doi.org/10.3390/biomedicines9060621>

- **Hospices Civils de Lyon**

Millet, A. *et al.* (2019). Determination of Cetuximab in Plasma by Liquid Chromatography–High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled ¹³C,¹⁵N-Cetuximab Internal Standard. *Therapeutic Drug Monitoring*, 41(4), 467-475. <https://doi.org/10.1097/ftd.0000000000000613>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2018). Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry. *Therapeutic Drug Monitoring*, 40(4), 417-424. <https://doi.org/10.1097/ftd.0000000000000514>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2016). Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry : towards a standardization of the methods ? *Analytical and Bioanalytical Chemistry*, 409(5), 1195-1205. <https://doi.org/10.1007/s00216-016-0045-4>

- **University Medical Center Utrecht**

el Amrani, M. *et al.* (2016). Quantification of active infliximab in human serum with liquid chromatography–tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard : A target-based, sensitive and cost-effective method. *Journal of Chromatography A*, 1454, 42-48. <https://doi.org/10.1016/j.chroma.2016.05.070>

PROMISE Proteomics S.A.S.

7, parvis Louis Néel • BHT 52 A • CS 20050 - 38040 Grenoble Cedex 9 • FRANCE

Phone: +33 438 023 650 | RCS Grenoble B 433 546 504